SWK Holdings Corp (NASDAQ: SWKH) is a specialty finance company that provides debt and royalty-based financing to companies in the life science sector. It makes money by generating interest income on secured loans and by owning or financing royalty and revenue interests tied to sales of life science products and related intellectual property. SWK targets transactions below $50.0 million in size, a segment it describes as underserved because larger specialty finance competitors typically prioritize deals above that threshold. Since inception of its strategy through March 7, 2026, SWK and its partners have executed transactions with 58 different counterparties, funding an aggregate of approximately $876.1 million across various financial products. As of December 31, 2025, consolidated finance receivables stood at $218.6 million, net of a $7.3 million allowance for credit losses, and the company generated $38.4 million of finance receivable interest income, including fees, for the year ended December 31, 2025. SWK was incorporated in California in July 1996 and reincorporated in Delaware in September 1999, commencing its specialty finance strategy in July 2012.

Revenue model

Interest income and fees on senior and subordinated debt secured by royalties and synthetic royalties; income from owned or financed royalty and revenue interests generated by sales of life science products and related intellectual property. Interest is recorded on an accrual basis using the effective interest rate method.

Products and services

Senior secured debt backed by royalties; subordinated debt backed by royalties and synthetic royalties; purchased royalty interests generated by life science product sales; revenue interest financing tied to life science intellectual property. Financing is provided through subsidiary SWK Funding LLC.

Customers and end markets

Life science companies requiring sub-$50.0 million non-traditional debt or royalty financings. End markets are pharmaceutical, biopharmaceutical, and broader life science sectors. As of March 7, 2026, the portfolio included transactions with 58 different counterparties since inception.

Value-chain role

Non-bank specialty lender and royalty financier positioned between traditional bank lenders and large-scale royalty acquirers. Provides capital to life science companies in exchange for debt service secured by product royalties or direct royalty interest ownership, without requiring equity dilution from borrowers.

Source: SEC 10-K, filed 2026-03-20

Industry: Miscellaneous Business Credit Institution Peers: Gold.com Inc Acacia Research Corp California First Leasing Corp FlexShopper, Inc. GWG Holdings, Inc. Sundance Strategies Inc LM Funding America Inc SUI Group Holdings Ltd